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Abstract
Background: Two commercial interferon gamma release assays (IGRAs) (QuantiFERON®-TB
Gold in Tube and T SPOT®-TB) to detect a contact with M. tuberculosis have recently become
available. The majority of studies agree that the sensitivity and specificity of these methods are
superior to the Tuberculin Skin Tests (TSTs) in detecting an exposure to bacteria in latently
infected individuals and in clinical tuberculosis. However, the data in children remains limited.
Findings: Consecutively collected samples from children (n = 99) representing age range from
zero to 18 years were analyzed in a retrospective non-blinded study. The two IGRAs were
modified and adapted to the needs of Finland, a country of a low tuberculosis incidence. For 27
children, both tests were performed simultaneously and compared with the TST and clinician's
diagnosis. The sensitivity, specificity, and accuracy of both IGRAs was determined. QuantiFERON
TB Gold and T SPOT-TB performed (respectively) as follows: sensitivities 0.92 (95% confidence
interval, CI, 0.67–0.99) and 0.85 (0.64–0.95); specificities 0.91 (0.77–0.97) and 1.00 (0.93–1.00);
accuracies 0.91 (0.80–0.97) and 0.96 (0.88–0.99). This compares favorably to the TST whose
known figures are 0.90, 0.95, and 0.95, respectively. The agreement between the IGRAs was high,
k = 0.89. Finally, both methods agreed well with the TST, k = 0.86 for TST/QuantiFERON-TB Gold
and k = 0.76 for TST/T SPOT-TB.
Conclusion: The sensitivity and specificity of IGRA methods compares well with the TST without
the inconveniences and complications associated with TST, including exaggerated delayed type
hypersensitivity reactions. These properties place them as acceptable substitutes for TST.
Background
Diagnosis of childhood tuberculosis (TB) remains chal-
lenging [1]. Two commercial IFN-γ release assays (IGRAs),
namely T-SPOT.TB and QuantiFERON®-TB Gold In-Tube
(QFGT), have been recently developed. These methods
show acceptable diagnostic accuracy for active TB in
adults [2] and have better correlation with tuberculosis
exposure than the TSTs in contact tracing for revealing
latent infections (LTBI) [3,4]. However, pediatric data are
limited, and studies evaluating the performance of IGRAs
in children have been called for especially in low-inci-
dence countries [2,5,6].
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In Finland the incidence of TB is low, 5.6/100 000 inhab-
itants in 2006 [7]. Only zero to six child TB diagnoses per
annum has been registered during the last ten years [8].
Universal BCG vaccination of newborns was practiced
until 2006 [9]
Between September 2004 and January 2007 our labora-
tory adapted the tests to the general needs in Finland.
After completion of the field evaluation [10] the methods
became available for routine diagnostics. We then evalu-
ated the performance of IGRAs in children and compared
them to the TST and clinical diagnoses.
Findings
Study Population
Between 15.9.2004 and 15.10.2007 we analyzed samples
from 99 consecutive children and adolescents. The flow
diagram of the study is presented in Fig. 1. We reviewed
the medical records of the patients and collected data on
demographics, clinical, microbiological and radiological
examinations, and the BCG vaccination history (Table 1).
Table 1: Characteristics of children enrolled in the study (n = 99)
Characteristic n
Male 63
Age (yrs), median (min-max) 9 (0–18)
BCG vaccinated* 68
BCG non-vaccinated 6
BCG vaccination status unknown 25
Born outside Finland or at least one of the parents is from a country with endemic TB: 57
➢ Somalia (several families) 25
➢ Vietnam 6
➢ Peru (1 family) 4
➢ Russia 4
➢ Kosovo 2
➢ Nigeria 2
➢ Afghanistan, Angola, Azerbadzan, Burma Burundi, Estonia, India, Congo, Sudan, Thailand, Turkey, Uganda 12 (one each)
➢ Siblings who live in Russia 2
HIV infection 2
TST test performed 87
TST not performed 8
Data missing 4
Culture or/and Nucleic acid amplification (NAA) method performed 6
➢ acid fast staining positive 2/6 (also culture pos)
➢ culture positive (M. tuberculosis) 4/6
➢ NAA positive 2/6 (also culture pos)
Radiological examination performed 95
Radiological findings
➢ normal 81/95 (85%)
➢ pulmonary TB 4
➢ enlargement of the hilus zone (Hodgkin lymphoma, TB lymphadenitis, one mild in LTBI, one mild in salmonelosis) 4 (one each)
➢ interstitial changes (vasculitis) 1
➢ pleural effusion (pleuritis and chylothorax) 2
➢ pneumonia 2
➢ bronchoectasia 1
Indications for IGRA-tests
➢ exposure to TB 62
➢ clinical signs compatible with TB 37
* All children born in Finland before September 2006 were supposed to be BCG vaccinated even if this was not mentioned in the record.BMC Research Notes 2009, 2:9 http://www.biomedcentral.com/1756-0500/2/9
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This study was approved by the Ethical Committee of the
Hospital for Children and Adolescents, University of Hel-
sinki (Nr.164/E7/05).
Ly-TbSpot procedure and quality control
The Ly-TbSpot, a modified version of T-SPOT.TB (Oxford
Immunotec, Oxford, UK) [11], was performed using
standard operation procedures (SOP). Firstly, the results
were expressed as a number of reactive spots/million lym-
phocytes. The lymphocyte count from isolated peripheral
blood mononuclear cell (PBMC) preparation was calcu-
lated with an automated hematologic analyzer (Advia® 60,
Bayer, Germany). Secondly, duplicate ELISPOT wells were
used for each antigen and media. Thirdly, Purified Protein
Derivative (PPD) (Statens Serum Institut, Copenhagen,
Denmark) was used as an additional positive control.
Fourthly, we adopted a double cut-off policy, i.e. the
responses below 25 spot/million lymphocytes were con-
sidered as non-reactive according to the guidelines by the
manufacturer; the responses between 25 and 55 spots
were considered borderline and over 55 spots were inter-
preted as reactive. An internal control of cryopreserved
cells was run with each new batch of reagents.
B-TbIFNγ procedure and quality control
B-TbIFNγ is a modified version of the QuantiFERON®-TB
Gold In-Tube (Cellestis Limited, Carnegie, Victoria, Aus-
tralia) [12]. In accordance with the SOP of our laboratory,
stimulation of blood cells was done in tubes of the man-
ufacturer. However, for measurement of IFN-γ levels, we
used EIA of PeliKine Compact human EIA (Sanquin,
Amsterdam, The Netherlands). This resulted in a steeper
calibration curve and ensured more accurate result inter-
pretation in the cut-off zone (Fig. 2). Two cut-off levels
were applied. The samples showing a net reactivity (the
reactivity of a sample minus the reactivity of the nil con-
trol) < 0.35 IU/ml were interpreted as non-reactive. Those
showing reactivity between 0.35 and 0.50 IU/ml were
interpreted as borderline and those with a reactivity
exceeding 0.50 IU/ml were interpreted as reactive. For the
The outline of the study design Figure 1
The outline of the study design. The (*) means that immunoconversion was observed in one patient. In this case the Ly-
TbSpot, the Mantoux test and the B-TbIFNγ were done and in August and repeated in December, the two were negative and 
the B-TbIFNγ was once borderline but the repeated B-TbIFNγ test and the Mantoux turned positive in February (for more 
details see Table 3).
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internal quality control, an artificially prepared IFN-γ
solution to simulate a low reactive sample was used.
Method of TST
TST was performed with two TU, purified protein deriva-
tive (PPD, RT23, Statens Serum Institut, Copenhagen,
Denmark) according to the Mantoux technique. The result
was recorded after 48–72 h. A cut-off for positivity was
defined as 10 mm or more in BCG-vaccinated and 5 mm
or more in non-vaccinated children. If a child had a nega-
tive TST result, but was examined because of contact with
an infectious TB case, the test was repeated [13].
Definitions
For methods evaluation we used conventional interpreta-
tions of definitive and probable TB and of LTBI.
Improvement of the calibration curve for IFNγ-measurement Figure 2
Improvement of the calibration curve for IFNγ-measurement. For measurement of IFN-γ levels, the original EIA rea-
gent from Cellestis (circles) was substituted by that of PeliKine Compact human EIA (squares). This resulted in a steeper cali-
bration curve and the use of the whole dynamic range of the photometer. Analytically, this means more accurate result 
interpretation in the cut-off zone. OD405 nm, optical densities measured at 405 nm.BMC Research Notes 2009, 2:9 http://www.biomedcentral.com/1756-0500/2/9
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Exclusion criteria
The results of the tests were considered eligible if the reac-
tivities to the mitogen were as suggested by the manufac-
tures. Seven samples were excluded from the ELISPOT
analysis because of high non-specific background.
Statistical analysis
The concordances between the IGRAs, and of each test
with the TST, were assessed in three categories by describ-
ing proportions of agreement (PA) and with the Cohen's
kappa statistic with linear weighting. 95% confidence
intervals (CI) were calculated with the Wilson efficient-
score method which was corrected for continuity. Using a
conservative approach, the cases interpreted in the grey
zone were placed into categories of false positives or false
negatives for the calculations of specificity, sensitivity and
accuracy.
Final diagnosis of the participants
Overall, 99 samples were analyzed, and their characteris-
tics are shown in Table 1, Table 2, and Figure 1. The sub-
jects were tested as follows: with the Ly-TbSpot alone,
with the B-TbINFγ alone, and with both Ly-TbSpot and B-
TbIFNγ. Participant numbers were 52, 20, and 27 (out of
99 total), respectively. Seven results were excluded from
calculations because non-specific background reactivity
made it impossible to interpret the samples as definitely
non-reactive. Of those tested with the Ly-TbSpot alone, six
cases were positive and one was a borderline case; of those
tested with the B-TbINFγ alone, one was interpreted as a
borderline and one was positive; of those tested with both
methods, 11 were positive by both methods and two sam-
ples were interpreted as borderline only with the B-
TbINFγ method. The majority of the patients were either
new immigrants or had at least one parent from a country
with a high incidence of TB. The median age of the partic-
ipants was nine years and the age range was from two
weeks to adolescence.
The major indication for performing IGRA was recent con-
tact with an infectious case of TB (62 of 99 patients).
Thirty-seven children were examined because of sympto-
matic illness, with TB considered a diagnostic modality.
Ten children were diagnosed with TB; five had pulmonary
TB, only one of them culture positive; five were diagnosed
with extrapulmonary TB. One patient also had an HIV
infection, and one patient was HIV infected but had no
TB.
Immunological conversion was observed in a 13-year-old
boy who was examined several times because of the
repeated household contacts with TB. His patient history
Table 2: Final diagnoses of the patients
Diagnosis Total number TST performed, number TST, mm median (range)
TB detected, n = 23 Pulmonary tuberculosis 5 5 16 (15–27)
➢ 1 acid fast staining and culture pos
➢ 4 with radiologic findings, history of contact 
and positive TST
Extrapulmonary tuberculosis 5 4 18.5 (16–30)
➢ 4 lymphadenitis (one HIV+), 3/4 culture 
positive
➢ 1 with clinical presentation and positive TST
LTBI 13 13 16 (10–27)
No TB detected, n = 76 Healthy contacts of TB cases 45 45 0 (0–9)
Abscesses of diverse localizations 4 3 0 (0–4)
Pneumonia or acute respiratory infection 5 5 0
BCG osteitis 2 2 13.5 (12–15)
Hypersedimentation due to obesity 2 2 0
Cysticercosis 2 1 0
Various infectious or inflammatory conditions, one 
each
16 9 0 (0–7)BMC Research Notes 2009, 2:9 http://www.biomedcentral.com/1756-0500/2/9
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and the kinetics of the immunological responses in all the
three methods are presented in Table 3.
The TST was performed in 87 (out of 99) subjects, in eight
the test was not performed, and in four the data was miss-
ing from the records. Of those tested, positive TST was
recorded in 25 cases, the size of the induration ranging
from 10 to 30 mm. In one subject the TST converted from
zero to 16 mm (Table 3). In another subject the TST test
caused a severe delayed type hypersensitivity reaction,
which resulted in a cosmetically unacceptable scar (Fig.
3A–C). A similar severe hypersensitivity reaction was
observed in a third case that was not enrolled in the cur-
rent study (Fig 3D, E).
Performance characteristics of the IGRAs
Combined performance characteristics for IGRAs are pre-
sented in Table 4. None of the samples tested with the Ly-
TbSpot were condemned as false positives, whereas three
samples fell into the borderline category with the B-
TbIFNγ (see Fig. 1). According to our interpretation crite-
ria, three patients in the Ly-TbSpot and one in the B-
TbIFNγ cohorts were grouped as false negatives. One was
a 7-year-old boy with tuberculous lymphadenitis who had
a borderline Ly-TbSpot result in our definition, but the
TST induration was 20 mm. The second was a 15-year-old
boy with TB contact who had TST induration of 13 mm
but his Ly-TbSpot results were repeatedly negative. The
third case was a 6-year-old girl with no symptoms whose
sibling was diagnosed with TB. She had a TST conversion
within a year, the TST induration at the time of assessment
was 10 mm, but both IGRAs remained non-reactive. The
fourth case was a 9-year-old boy from a highly endemic
area whose TST induration was 11 mm but the B-TbIFNγ
remained non-reactive. Because of the lack of the gold
standard for LTBI, in the last three cases the diagnosis was
based primarily on extensive exposure to TB and positive
TST, in accordance with the recommendations in our
country [13].
Agreement between Ly-TbSpot, B-TbIFNγ and the TST
The calculated data are presented in Table 5. The κ values
above 0.75 imply good agreement, more than might have
occurred by chance.
Analysis of non-interpretable results
Non-specific background activation of cells for IFNγ pro-
duction was observed in seven samples analyzed with the
Ly-TbSpot. Of those, six samples were from members of a
family newly immigrated from Ethiopia. These patients
showed reactivity without stimulation with an added anti-
gen, the size of the spots being very small. This non-spe-
cific reactivity was interpreted as the reactivity of other
than effector T-cell populations, most probably of NK
cells. All results obtained with the B-TbIFNγ-method were
acceptable.
The influence of the cut-off levels on performance 
characteristics of the Ly-TbSpot
Theoretical values for sensitivity, specificity, positive and
negative predictive values were plotted against differential
cut-off points. The analysis showed that the accuracy of
the test peaked to 0.97 in the range of 24 to 48 spots/mil-
lion lymphocytes (Fig. 4). Hence, by preserving our cur-
rent double cut-off policy, and a conservative way of
interpretation, we achieved an accuracy of 0.96. This
means that any pediatric sample falling into the border-
line category may most probably represent a pathological
condition.
We present results of a retrospective, non-blinded study of
two modified IGRAs for the diagnosis of childhood TB.
The modifications were aimed to avoid false positive
interpretations. Because no method can guarantee 100%
sensitivity and specificity, we made a pragmatic decision
Table 3: Anamnestic data and the observed kinetics of immunological conversion in a 13-year-old boy.
Time 2007.07 2007.08 2007.09 2007.11 2007.12 2008.02
Anamnesis A visitor in the family 
with pulmonary 
TB(AFB+)
The grandparent 
diagnosed with 
culture-positive TB
TST (mm) 0 (neg) 16 (conversion)
Ly-TbSpot (reactive 
cells/106 
lymphocytes.
17 (non-reactive) 13 (non-reactive) nd nd
The max response is 
shown
B-TbINFγ (IU/ml) 0.36 (borderline) nd 0.15 (non-reactive) 0.70 (reactive)BMC Research Notes 2009, 2:9 http://www.biomedcentral.com/1756-0500/2/9
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to offer the best possible specificity even at the cost of sen-
sitivity. Changing of the cut-off levels of the commercial
IGRA methods has been suggested by other investigators.
Lee at al [14] suggested lowering the cut-off in the QFGT
method. This change would have resulted in a drop of spe-
cificity from 91.6% to 87.0% which we, contrary to Lee,
do not regard as a minimal loss. Arend et al [15] also rec-
ommended dropping the cut-off of the QFGT to achieve a
detection rate of potentially infected persons similar to
that of TST. The recommendation is not acceptable for the
reason that TST is by no means a gold standard. The sen-
sitivity of QFGT could instead be improved e.g. by using
Exaggerated delayed type hypersensitivity reaction in the TST leading to a permanent scar Figure 3
Exaggerated delayed type hypersensitivity reaction in the TST leading to a permanent scar. The upper panel rep-
resents results of the TST in a 14-year-old boy with LTBI, A taken three days, B two weeks and C three months after inocula-
tion of 2 TU of PPD RT23. The original size of the induration was 20 mm. Photos: Courtesy of Dr. Peter Floman, Hospital of 
Porvoo. The lower panel represents results of the TST in a 13-year old girl with TB lymphadenitis, D taken 3 days and E two 
weeks after performing TST. This child was not enrolled in the current study.
Table 4: Performance characteristics of the IGRA-methods.
Parameter Sensitivity (95% CI§) Specificity 95% CI) PPV† (95% CI) NPV‡ (95% CI) Accuracy (95% CI)
Method
Ly-TbSpot 0.85 1.00 1.00 0.96 0.96
n = 72 (0.64 – 0.95) (0.93 – 1.00) (0.82 – 1.00) (0.87 – 0.99) (0.88 – 0.99)
B-TbIFNγ 0.92 0.91 1.00 0.96 0.91
n = 41 (0.67 – 0.99) (0.77 – 0.97) (0.76 – 1.00) (0.84 – 0.99) (0.80 – 0.97)
* Pre-test probability, † Positive predictive value, ‡ Negative predictive value, §Confidence interval.BMC Research Notes 2009, 2:9 http://www.biomedcentral.com/1756-0500/2/9
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more sensitive EIA techniques. In fact, although there was
high agreement between IGRAs and TST in our studies,
three earlier studies found a lower agreement: two studies
[16,17] performed on pediatric samples in low risk coun-
tries observed concordant results between the IGRAs but
inferior specificity of the TST, and one large cohort study
of TB disease in African children [18] found lower agree-
ment with the TST. In another cohort study of contact trac-
ing, performed on Gambian children, the clinical
sensitivity of the TST was found superior to that of the
ELISPOT in diagnosing LTBI [19]. In that study, however,
the discordance between the tests was not significant [19].
In a recent study from Gambia [20] comparing the new
IGRAs to TST in contact tracing, ELISPOT was found more
sensitive than the QFGT in the diagnosis of TB disease
while equally sensitive in the diagnosis of LTBI. That study
showed no significant discordance between IGRAs but the
results of the TST were influenced by the BCG vaccination
status. The observed discrepancies in the estimation of the
three methods are most probably attributed to the differ-
ences in the research population, their vaccination status
and exposure to other mycobacteria, and most impor-
tantly, in the variability of the methods' performance
using variable threshold levels.
Table 5: Agreement between Ly-TbSpot, B-TbIFNγ and the TST
Test pair n Agreementpos/neg Proportions of agreement (95% CI) κ (95% CI)
Ly-TbSpot B-TbIFNγ 27 11/13 0.89 (0.70 – 0.97) 0.89 (0.77 – 1.00)
Ly-TbSpot TST 62 16/39 0.89 (0.77 – 0.95) 0.76 (0.59 – 0.92)
B-TbIFNγ TST 43 11/28 0.90 (0.77 – 0.97) 0.86 (0.72 – 1.00)
Test parameters of Ly-TbSpot using differential cut-off points (n = 72) Figure 4
Test parameters of Ly-TbSpot using differential cut-off points (n = 72). Theoretical values for sensitivity (blue), spe-
cificity (red), positive (dashed purple) and negative predictive values (dashed grey) on the y-axis were plotted against the cut-off 
points on the x-axis. The accuracy (black) of the tests peaked to 0.97 in the range of 24 to 48 spots/million lymphocytes. 
Hence, by preserving our current double cut-off policy (25 and 55 spots/million lymphocytes) we achieve an accuracy of 0.96.BMC Research Notes 2009, 2:9 http://www.biomedcentral.com/1756-0500/2/9
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Our study raises several important issues. When perform-
ing TST, intradermal inoculation of PPD in children
exposed to M. tuberculosis may produce an excessive
delayed type hypersensitivity reaction. Secondly, demon-
stration of the test variability around the cut-off zone in
real laboratory settings convinces that interpretation of
immunodiagnostic methods should take into account the
method imprecision and utilize a grey zone.
Conclusion
The sensitivity and specificity of IGRA methods compares
well with TST but do not cause exaggerated delayed type
hypersensitivity reactions.
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